Innate Pharma falls on FDA's partial hold on cancer drug trial

Innate Pharma SA

05/10/2023 19:51

** U.S.-listed shares of French biopharma co Innate Pharma
SA  IPH.PA  fall 9.51% to $2.23
    ** Co says U.S. Food and Drug Administration (FDA) has
placed a partial clinical hold on two trials studying co's
lacutamab leading to a pause in new patient enrollment
    ** The partial clinical hold follows one fatal case of
hemophagocytic lymphohistiocytosis, a rare blood disorder
     ** Co's ongoing mid-stage trial is fully recruited, final
data is expected in Q4 2023
    ** Lacutamab is an antibody that is currently in trials for
treatment of cutaneous T-cell lymphoma, a rare type of cancer
    ** U.S.-listed stock is down ~40% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))